【重磅】新药呲仑帕奈为数百万癫痫患者带来治疗新选择！

Epilepsy is one of the most common and serious neurological diseases, affecting approximately more than 50 million people worldwide. Although there are currently as many as 28 different anti-seizure drugs (ASMs), approximately one-third of patients still have uncontrollable seizures. Therefore, ASMs with new mechanisms of action have aroused great interest, which will improve the efficacy of epilepsy treatment. Perampanel is a third-generation new ASMs that was recently approved for the monotherapy of focal epilepsy. It has a unique and selective mode of action on the α-amino-3-hydroxy-5-methyl 4-isoxazolepropionic acid (AMPA) receptor. Paraampanel exerts anti-epileptic effects by non-competitively binding to AMPA receptors, thereby inhibiting glutamate-induced excessive neurotransmission. Even when glutamate levels increase, it will not be replaced by glutamate, maintaining the effect of antagonizing AMPA receptors and prolonging the drug's action time.

After oral administration, perampanel is rapidly and completely absorbed, and the peak drug effect in the fasting state is 0.5 to 2.5 hours. Eating does not affect the degree of absorption, but it will slow down the absorption rate. The peak concentration of the drug is 28% to 40% lower than that in the fasting state, and the peak drug effect time is delayed by 2 to 3 hours. The average half-life is 105 hours, and the half-life is extended in patients with liver insufficiency.

Perampanel was the first AMPA receptor antagonist to receive regulatory approval. In 2012, the US FDA approved the marketing of oral tablets of parampanel, and it can only be used as an add-on treatment for patients with focal epileptic seizures aged 12 years and above. Japan obtained indications for parampanel monotherapy in January 2020. Perampanel was launched in my country in September 2019. It is used once a day as an add-on treatment for focal epilepsy aged 12 years and above. In July 2020, it received clinical-free approval for monotherapy.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.